Table 1 Quantification of HBV variants and its clinical application
| Â | Nie et al. [19] | Yang et al. [20] | Tseng et al. [21] | Bayliss et al. [22] |
|---|---|---|---|---|
Quantification assay | Selective inhibitory polymerase chain reaction | Pyrosequencing | Pyrosequencing | Next generation sequencing |
Target region | PC (G1896A) & BCP (A1762T/G1764A) mutants | PC (G1896A) & BCP (A1762T/G1764A) mutants | BCP mutants (A1762T/G1764A) | HBV whole genome |
Sensitivity to detect minor strains | <1% | 10% | 10% | <1% |
Enrolled patients | 18 HBeAg-positive patients | 203 HBeAg-positive patients receiving interferon-based treatment | 151 HBeAg-negative patients with a median follow-up period of 9Â years. | 157 HBeAg-positive patients receiving 4-year tenofovir treatment |
Main finding | Levels of PC and BCP mutants may predict the time of HBeAg seroconversion | Quantitative analysis of PC and BCP mutants can predict interferon-induced HBeAg seroconversion | A higher percentage of BCP mutant is associated with higher risks of cirrhosis development | Detectable BCP or PC mutants are associated with a lower probability of HBsAg loss during tenofovir therapy. |